Comer Holdings

Comera Life Sciences is a pre-clinical stage biotechnology company specializing in the development of formulation technologies for biologic medicines. The company's proprietary SQore™ platform utilizes computational chemistry and a library of excipients to reduce the viscosity of high-concentration protein solutions, facilitating the transition from intravenous to subcutaneous administration. This technology aims to improve patient experience and healthcare efficiency by allowing for self-administration of complex therapies. Comera's portfolio includes internal 'bio-better' programs and research collaborations with major pharmaceutical companies like Bayer. Despite its innovative platform, the company filed for Chapter 11 bankruptcy in May 2024 following its delisting from the Nasdaq exchange.